Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

NCT00757042 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Healthy Volunteers

Interventions

DRUG: Tezepelumab
DRUG: Placebo

Sponsor

Amgen